Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 12

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 12
---
ramed. |

8

| • |     | “Tranche B Notes” means those certain tranche B senior secured convertible notes issued by us on                                           
 October 8, 2024 to the Tranche B Noteholders, due on the second anniversary of the issuance date in the principal amount of $50.0 million. |

| • |     | “Units” means the units of Vickers, each of which consisted of one Vickers Ordinary Share and one-half of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without 
 any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock.                                                                                                             |

| • |     | “Vickers” means Vickers Vantage Corp. I, our predecessor company. |

| • |     | “Vickers Ordinary Shares” means (i) the ordinary shares, par value $0.0001 per share,        
 of Vickers prior to the Domestication and (ii) the Common Stock following the Domestication. |

| • |     | “Yorkville” means YA II PN, Ltd., a Cayman Islands exempt limited partnership. |

9

PROSPECTUS SUMMARY

This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

The Company

We are an innovative
revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and
large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.

Our commercial products are: (i)